Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
BACKGROUND
India, the largest developing country, has a steadily rising incidence of breast cancer. Estimates and comparisons of the cost-effectiveness of feasible breast cancer screening policies in developing countries and identification of the determinants of cost and efficacy are needed.


METHODS
A Microsimulation Screening Analysis model of breast cancer was calibrated to available data on breast cancer incidence, stage distribution, and mortality in India. The model was used to estimate the costs of screening for breast cancer in India, its effects on mortality, and its cost-effectiveness (ie, costs of screening per life-year gained or life saved). Screening using clinical breast examination (CBE) or mammography among different age groups and at various frequencies was analyzed. Costs were expressed in international dollars (Int.$), the currency used by the World Health Organization, which has the same purchasing power in India as the US dollar has in the United States. To determine which factors influenced cost-effectiveness, sensitivity analyses were performed.


RESULTS
The estimated mortality reduction was the greatest for programs targeting women between age 40 and 60 years. Using a 3% discount rate, a single CBE at age 50 had an estimated cost-effectiveness ratio of Int.$793 per life year gained and a breast cancer mortality reduction of 2%. The cost-effectiveness ratio increased to Int.$1135 per life year gained for every-5-year CBE (age 40-60 years) and to Int.$1341 for biennial CBE (age 40-60 years); the corresponding reductions in breast cancer mortality were 8.2% and 16.3%, respectively. CBE performed annually from ages 40 to 60 was predicted to be nearly as efficacious as biennial mammography screening for reducing breast cancer mortality while incurring only half the net costs. The main factors affecting cost-effectiveness were breast cancer incidence, stage distribution, and cost savings on prevented palliative care.


CONCLUSIONS
The estimated cost-effectiveness of CBE screening for breast cancer in India compares favorably with that of mammography in developed countries. However, in view of competing priorities and economic conditions, the introduction of screening in India represents a greater challenge than it has been in more developed countries.
Okonkwo
Quirine Lamberts
QL
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
Draisma
Gerrit
G
der Kinderen
Arno
A
Brown
Martin L
ML
de Koning
Harry J
HJ
D000328:Adult; D001943:Breast Neoplasms / Q000191:economics* / Q000453:epidemiology / Q000401:mortality* / Q000473:pathology; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D008327:Mammography / Q000191:economics*; D008403:Mass Screening / Q000191:economics* / Q000379:methods*; D008875:Middle Aged; D009367:Neoplasm Staging; D010173:Palpation / Q000191:economics*; D011237:Predictive Value of Tests